Evidence map›Paper›PMID 36750609›Full record

Observational studyHypertension research : official journal of the Japanese Society of Hypertension2023

Association of triglycerides to high-density lipoprotein cholesterol ratio with incident cardiovascular disease but not end-stage kidney disease among patients with biopsy-proven diabetic nephropathy.

Takayuki Uemura, Masatoshi Nishimoto, Masahiro Eriguchi, Hiroyuki Tamaki, Hikari Tasaki, Riri Furuyama, Fumihiro Fukata, Takaaki Kosugi, Katsuhiko Morimoto, Masaru Matsui and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Review
  6. Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Takayuki UemuraDepartment of Nephrology, Nara Medical University, Nara, Japan.
Masatoshi NishimotoDepartment of Nephrology, Nara Medical University, Nara, Japan.
Masahiro EriguchiDepartment of Nephrology, Nara Medical University, Nara, Japan. meriguci@gmail.com.
Hiroyuki TamakiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Hikari TasakiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Riri FuruyamaDepartment of Nephrology, Nara Medical University, Nara, Japan.
Fumihiro FukataDepartment of Nephrology, Nara Medical University, Nara, Japan.
Takaaki KosugiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Katsuhiko MorimotoDepartment of Nephrology, Nara Prefecture Seiwa Medical Center, Nara, Japan.
Masaru MatsuiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Ken-Ichi SamejimaDepartment of Nephrology, Nara Medical University, Nara, Japan.
Kazuhiko TsuruyaDepartment of Nephrology, Nara Medical University, Nara, Japan.
Nara Medical University · JPNara Medical University Hospital · JPNara Prefecture General Medical Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) are dyslipidemias characteristic of diabetes. Here, we aimed to examine associations of TG/HDL-C ratio with cardiovascular disease (CVD) and kidney dysfunction among patients with diabetic nephropathy. This retrospective observational study consists of patients with biopsy-proven diabetic nephropathy at Nara Medical University Hospital. Exposure of interest was TG/HDL-C ratio measured at kidney biopsy. Outcome variables were kidney histological findings, incident CVD and end-stage kidney disease (ESKD). Multivariable logistic regression models and Cox proportional hazard models were used to examined these associations. A total of 353 subjects were divided into quartiles based on TG/HDL-C ratio: Quartile 1 (reference), <1.96; Quartile 2, 1.96-3.10; Quartile 3, 3.11-4.55; and Quartile 4, ≥4.56. TG/HDL-C ratio was not a predictor of any histological findings in fully adjusted models. During median follow-up periods of 6.2 and 7.3 years, 152 and 90 subjects developed CVD and ESKD, respectively. Higher TG/HDL-C ratio was independently associated with higher incidences of CVD even after adjustments for potential confounders (hazard ratio [95% confidence interval] for Quartile 3 vs. reference; 1.73 [1.08-2.79] and Quartile 4 vs. reference; 1.86 [1.10-3.17]). Although there was a weak association between TG/HDL-C ratio and ESKD in the univariable model, the association was not significant in fully adjusted models. In conclusion, among patients with biopsy-proven diabetic nephropathy, higher TG/HDL-C ratio was independently associated with higher incidences of CVD but not with kidney outcomes, suggesting different impact of TG/HDL-C ratio on cardiorenal outcomes.

Indexed as

Cardiovascular DiseasesDiabetes MellitusDiabetic NephropathiesKidney Failure, ChronicCholesterol, HDLHumansRisk FactorsTriglyceridesCholesterol, HDLTriglyceridesCardiovascular diseaseDiabetic nephropathyEnd-stage kidney diseaseKidney biopsyTriglycerides to high-density lipoprotein cholesterol ratio.

Identifiers

PMID36750609
OpenAlexW4319439632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.